YASMIN NEWS HIGHLIGHTS Media Articles Related to Yasmin (Ethinyl Estradiol)
N.C. Senate Approves Bill To Offer Contraception, STI Information In School Sex Education Courses
Source: Sexual Health / STDs News From Medical News Today [2009.06.26]
The North Carolina Senate on Tuesday voted 25-21 to approve a bill (S. 221) that would require public school systems in the state to offer a sex education curriculum that includes information on abstinence, contraceptives and sexually transmitted infections, the
FDA Approves Generic Version Of Emergency Contraception Pills
Source: Sexual Health / STDs News From Medical News Today [2009.06.26]
FDA on Wednesday approved Watson Pharmaceuticals' generic version of the emergency contraceptive Plan B, the Wall Street Journal reports. The generic drug will be available without a prescription to women ages 18 and older on Aug. 24, when Duramed Pharmaceuticals' market exclusivity for Plan B expires (Kalish, Wall Street Journal, 6/25).
N.C. Bill Gives Students 'Vital Access' To Accurate Sex Education Instruction, Editorial States
Source: Sexual Health / STDs News From Medical News Today [2009.06.30]
A bill (S. 221) approved by the North Carolina Legislature that would require a public school sex education curriculum covering abstinence, contraception and sexually transmitted infections "will be the most comprehensive and science-based approach the state has used" for sex education, a
Published Studies Related to Yasmin (Ethinyl Estradiol)
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. [2008.11]
BACKGROUND: The study was conducted to investigate the effect of a combined oral contraceptive (COC) containing 30 mcg ethinylestradiol and 2 mg dienogest with two different regimens on various hemostasis variables... CONCLUSION: In general, these results were in agreement with those observed during treatment with other COCs. The study demonstrated that during conventional and extended-cycle treatment with EE/DNG, a steady-state in the effects on hemostasis variables was reached within 3 months, and that the effects observed after 3 and 12 months of treatment did not substantially differ between conventional and extended-cycle regimen.
Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. [2008.10]
OBJECTIVE: To assess the efficacy of the combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol [generic for Yasmin] (3-mg drospirenone/20-microgram ethinyl estradiol) administered as 24 consecutive days of active treatment after a 4-day hormone-free interval (24/4 regimen) compared with placebo for the treatment of moderate acne vulgaris... CONCLUSION: The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne. The safety profile was consistent with low-dose combined oral contraceptive use.
Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]
BACKGROUND: In postmenopausal women, declining estrogen levels are associated with a variety of skin changes, many of which are reportedly improved by estrogen supplementation. OBJECTIVE: A study was conducted to assess the effects of continuous combined norethindrone acetate (NA) and ethinyl estradiol [generic for Yasmin] (EE) in the control of mild to moderate age-related skin changes in postmenopausal women... CONCLUSION: Low-dose hormone therapy for 48 weeks in postmenopausal women did not significantly alter mild to moderate age-related facial skin changes.
A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. [2008.08]
This study compared the efficacy of a low-dose combined oral contraceptive (COC) containing 3-mg drospirenone and 20-microg ethinyl estradiol [generic for Yasmin] (3-mg DRSP/20-microg EE) administered in a 24-day active pill/4-day inert pill (24/4) regimen and placebo in women with moderate acne vulgaris during 6 treatment cycles... The COC 3-mg DRSP/20-microg EE 24/4 regimen is a suitable option for women with moderate acne vulgaris who require contraception.
Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users. [2008.08]
CONCLUSION: There was a decrease in spotting but no effect on bleeding with EE compared to PL.
Clinical Trials Related to Yasmin (Ethinyl Estradiol)
Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers [Completed]
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women [Completed]
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8
weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the
relief of vasomotor symptoms and who have hypertension.
Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women [Completed]
The objective of this study was to investigate the impact of the oral contraceptive YASMIN
(containing: drospirenone 3 mg/ethinyl estradiol 30 mcg) in comparison with the oral
contraceptive MICROGYNON (containing: levonorgestrel 150 mcg/ethinyl estradiol 30mcg) on
factors of blood coagulation and fibrinolysis in female subjects
A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Compared With Placebo In The Treatment Of Hidradenitis Suppurativa [Recruiting]
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and
effective for treating hidradenitis suppurativa. Hidradenitis suppurativa (HS) is a chronic
(long lasting) skin disorder that mostly affects the armpits and groin area. It appears as
blackheads and one or more red, tender bumps that may enlarge, break open, and drain pus.
Scarring may result after several attacks of the disease.
The exact cause of HS isn't known. However, it is believed that the plugging of hair
follicles and bacterial infection that occur in acne also occur in HS. Many of the
medications used for treating acne are also used for HS. However, none of the medications
are consistently effective.
YAZ is a combination birth control pill. Nearly all birth control pills are made up of a
combination of estrogen and progestin hormones. YAZ contains ethinyl estradiol (an estrogen)
and drospirenone (a progestin). People who develop acne have sebaceous glands that are
over-stimulated by male sex hormones (androgens). Sebaceous glands secrete an oily substance
into a hair follicle to lubricate hair or skin. The progestin in YAZ actually blocks the male
sex hormones (androgens) that cause acne. Hormones seem to play a role in HS as the condition
occurs after puberty. It affects more women than men and HS often gets worse around the time
a women has her menstrual period.
YAZ has been approved by the U. S. Food and Drug Administration (FDA) to treat moderate acne
in women who desire an oral contraceptive for birth control.
This study uses a placebo. A placebo looks like the study drug but contains no active drug.
We use placebos in research studies to learn if the effects seen in research subjects are
truly from the study drug or from other reasons.
A Study to Examine the Safety and Efficacy Of Drospirenone and Ethinyl Estradiol (YAZ) Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris [Recruiting]
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and
effective for treating acne on the trunk (the main part of the body that does not include the
arms, legs, and head).
Acne vulgaris is a very common skin disorder. It is caused when oil-producing skin glands
(sebaceous glands) become plugged. The plug can cause blackheads, whiteheads, pimples, and
cysts on the face, neck, upper chest, and upper back.
YAZ is a combination birth control pill. A "combination" pill means that it is made up of
more than one major ingredient. Nearly all birth control pills are made up of a combination
of estrogen and progestin hormones. Estrogens are steroid hormones produced by the ovaries
responsible for the typical female features. Progestins are steroid hormones produced by the
ovary and placenta responsible for making the uterus fit for pregnancy. YAZ also contains an
estrogen called ethinyl estradiol, and a progestin called drospirenone. People who develop
acne have sebaceous glands that are over-stimulated (that is, the sebaceous glands have
increased activity) by male sex hormones (androgens). The progestin in YAZ blocks the male
sex hormones (androgens) that cause acne.
The study drug being used in this study is called YAZ. It has been approved by the U. S. Food
and Drug Administration (FDA) to treat moderate acne in women who want an oral contraceptive
for birth control.
In this study, YAZ will be compared to a placebo for safety and effectiveness. A placebo
looks like the study drug but contains no active drug (like a sugar pill). We use placebos
in research studies to learn if the effects seen in research subjects are truly from the
study drug or from other reasons.
|
